Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh
October 6, 2021 5:44 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering... More
Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement
October 4, 2021 4:05 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) files mixed shelf registration statement of:
Common Shares
Preferred Shares
Warrants
Units
Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies
October 4, 2021 11:23 AM EDTJefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel
October 4, 2021 10:39 AM EDTStifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.
The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More
Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
October 4, 2021 7:01 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients... More
Xenon Pharmaceuticals (XENE) Halted, News Pending
October 4, 2021 6:55 AM EDTXenon Pharmaceuticals (NASDAQ: XENE) Halted, News Pending
... MoreXenon Pharmaceuticals (XENE) Schedules Webcast for October 4th, 7AM EST to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
October 4, 2021 5:46 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b X-TOLE clinical trial on Monday, October 4, 2021 at 7:30 am Eastern... More
